Selected 2026 research signals.
A compact reference page for literature that is particularly relevant to PIRIA’s positioning.
AI in target identification is becoming more disciplined.
Recent work in Nature Reviews Drug Discovery frames AI not as magic automation, but as a force multiplier for target identification, assessment and closed-loop experimentation—provided that validation remains central.
Pun FW et al. Nat Rev Drug Discov 25, 534–552 (2026). DOI: 10.1038/s41573-026-01412-8.Liquid biopsy is expanding from tumor burden to immune monitoring.
The July 2026 review on liquid-biopsy-based analysis of antitumour immunity is especially relevant for longitudinal, less-invasive monitoring concepts.
Pantel K, Masmoudi D, Alix-Panabières C. Nat Rev Clin Oncol. DOI: 10.1038/s41571-026-01181-8.AI-assisted organ-at-risk contouring has practical, real-world value.
Operational success matters. A multi-centre real-world 2026 study demonstrated the relevance of AI-assisted contouring to treatment-planning workflows rather than only to lab benchmarks.
Inverarity C et al. Br J Radiol. 2026;99(1184):1615–1623. DOI: 10.1093/bjr/tqag111.AI biomarker quantification in TNBC is being independently validated.
The 2026 Lancet Oncology validation study on AI-based TIL quantification in triple-negative breast cancer is notable because it moves beyond model development toward broader evaluation.
Dixon-Douglas JR et al. Lancet Oncol. 2026;27(9):1181–1192. DOI: 10.1016/S1470-2045(26)00339-6.Breast cancer response prediction remains a practical AI use case.
Imaging-based prediction of response to neoadjuvant treatment in TNBC remains an active and clinically relevant field, with 2026 work adding further support for this direction.
Diagnostic and Interventional Radiology. 2026. PMID 41140117.